Skip to main navigation Skip to search Skip to main content

Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: Anti-cancer activity in vitro and in vivo

  • T. Nie
  • , C. C. Wong
  • , N. Alston
  • , P. Aro
  • , P. P. Constantinides
  • , B. Rigas
  • Stony Brook University
  • Medicon Inc.

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

BACKGROUND AND PURPOSE Phospho-ibuprofen (P-I; MDC-917) inhibits the growth of colon cancer in mice. Here, we investigated the use of nanocarriers to improve its pharmacokinetics (PKs) and anti tumour efficacy. EXPERIMENTAL APPROACH The cellular uptake and cytotoxicity of P-I encapsulated into liposomes and micelles, and its in vitro metabolic stability, were determined in cultures of human colon adenocarcinoma cells. The performance of liposomal P-I was further evaluated in PK studies in mice, and in a model of colon cancer xenografts in nude mice. KEY RESULTS Liposomal P-I and micellar P-I showed significantly enhanced cellular uptake in the colon cancer cells. Liposomal P-I also demonstrated increased cytotoxicity in vitro. Free P-I was metabolized rapidly to ibuprofen in the presence of purified esterases. In contrast, liposomal P-I, and to a lesser extent micellar P-I, was resistant to esterase-mediated hydrolysis. In mice, liposomal P-I partially protected P-I from hydrolysis in the circulation, and improved the biodistribution of intact P-I and its metabolites compared to free P-I. Liposomal P-I was more effective at inhibiting the growth of human colon cancer xenografts in mice, which may be explained on the basis of its improved PK profile compared to free P-I. CONCLUSIONS AND IMPLICATIONS Liposome encapsulation of P-I partially protected P-I from esterase-mediated hydrolysis in mice, enhanced the cytotoxicity and bioavailability of P-I and increased its efficacy at inhibiting the growth of human colon cancer xenografts. These results indicate that liposomes are suitable nanocarriers for the delivery of P-I, and that the anti-tumour potential of liposomal P-I merits further evaluation.

Original languageEnglish
Pages (from-to)991-1001
Number of pages11
JournalBritish Journal of Pharmacology
Volume166
Issue number3
DOIs
StatePublished - Jun 2012

Keywords

  • liposome
  • micelle
  • pharmacokinetics
  • phospho-ibuprofen

Fingerprint

Dive into the research topics of 'Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: Anti-cancer activity in vitro and in vivo'. Together they form a unique fingerprint.

Cite this